Partial Mayo score consisted of 3 components: rectal bleeding, stool frequency, and physician (doctors) assessment of disease activity. Each sub score ranged from 0 to 3 (0=normal, 1=mild, 2=moderate, 3=severe). These sub scores were summed up to give a total score range of 0 to 9, where higher scores indicated higher disease severity. Index was considered as date of initiation of tofacitinib treatment for ulcerative colitis. Partial Mayo scores and sub-scores have been collected by doctors independently as part of standard of care.

Endoscopic findings were graded from 0 to 3 where 0 = Normal or inactive disease (Normal vascular pattern with arborization of capillaries clearly defined, or with blurring or patchy loss of capillary margins), 1 = Mild disease (erythema, decreased vascular pattern, mild friability), 2 = Moderate disease (marked erythema, absent vascular pattern, friability, erosions), 3 = Severe disease (spontaneous bleeding, ulceration). Index was considered as date of initiation of tofacitinib treatment for ulcerative colitis.

Endoscopic findings were graded from 0 to 3 where 0 = Normal or inactive disease, 1 = Mild disease (erythema, decreased vascular pattern, mild friability), 1 = Mild disease (erythema, decreased vascular pattern, mild friability), 3 = Severe disease (spontaneous bleeding, ulceration). Mayo score was composed of four components: rectal bleeding, stool frequency, physician assessment of disease activity and endoscopy findings. Each sub score ranged from 0 to 3 (0=normal, 1=mild, 2=moderate, 3=severe). These sub scores were summed up to give a total score range of 0 to 12, where higher scores indicated higher disease severity. Index was considered as date of initiation of tofacitinib treatment for ulcerative colitis.

Clinical remission in participants was defined as a partial Mayo score of less than 2 points with rectal bleeding sub-score of 0. Partial Mayo score consisted of 3 sub scores: rectal bleeding, stool frequency, physician assessment of disease activity. Each sub score ranged from 0 to 3 (0=normal, 1=mild, 2=moderate, 3=severe). These sub scores were summed up to give a total score range of 0 to 9, where higher scores indicated higher disease severity.

Clinical response in participants was defined as a full Mayo score decrease of greater than or equal (>=) to 3 points and a decrease of >=30 percent (%) from baseline, with a decrease of >=1 point on the rectal bleeding sub score or an absolute rectal bleeding score of less than equal to (<=)1. Full Mayo score consisted of 4 sub scores: rectal bleeding, stool frequency, physician assessment of disease activity, and endoscopy findings. Each graded from 0 to 3 (0=normal, 1=mild, 2=moderate, 3=severe). These sub scores were summed up to give a total score range of 0 to 12, where higher scores indicated higher disease severity.

Clinical response in participants was defined as a partial Mayo score decrease of >=2 points and reduction of at least 25% in partial Mayo score from baseline with an accompanying decrease in rectal bleeding sub score of >=1 point or absolute rectal bleeding sub score of <=1. Partial Mayo score consisted of 3 sub scores: rectal bleeding, stool frequency, physician assessment of disease activity. Each graded from 0 to 3 (0=normal, 1=mild, 2=moderate, 3=severe). These sub scores were summed up to give a total score range of 0 to 9, where higher scores indicated higher disease severity.

Clinical remission in participants was defined as a full Mayo score of <=2 points, with no individual sub score exceeding 1 point with rectal bleeding sub-score of 0. Full Mayo score consisted of 4 sub scores: rectal bleeding, stool frequency, physician assessment of disease activity, and endoscopy findings, each graded from 0 to 3 (0=normal, 1=mild, 2=moderate, 3=severe). These sub scores were summed up to give a total score range of 0 to 12, where higher scores indicated higher disease severity.

Clinical remission in participants was defined as a partial Mayo score of less than 2 points with rectal bleeding sub-score of 0. Partial Mayo score consisted of 3 sub scores: rectal bleeding, stool frequency, physician assessment of disease activity. Each graded from 0 to 3 (0=normal, 1=mild, 2=moderate, 3=severe). These sub scores were summed up to give a total score range of 0 to 9, where higher scores indicated higher disease severity. Steroid-free clinical remission was defined for participants who were treated with corticosteroids at baseline and did not require any corticosteroid treatment during the period >=4 weeks prior to the visit.

Time to clinical response was analyzed using a competing risk time-to-event model, where clinical response and drug discontinuation were assessed. Clinical response in participants was defined as full Mayo score decrease of >=3 points & decrease of >=30% from baseline, with decrease of >=1 point on rectal bleeding sub score or absolute rectal bleeding score of <=1. Full Mayo score consisted of 4 sub scores: rectal bleeding, stool frequency, physician assessment of disease activity, & endoscopy findings. Each graded from 0 to 3 (0=normal, 1=mild, 2=moderate, 3=severe). Sub scores were summed up to give total score range: 0 to 12, Partial Mayo score consisted of 3 components without endoscopy findings. Each graded from 0 to 3, sub scores were summed up to give total score range: 0 to 9.Higher scores indicated higher disease severity.

F-calprotectin is an inflammatory marker for the gastrointestinal tract and considered as a measurement of neutrophil migration to the gastrointestinal tract. Percentage of participants with F-calprotectin reduction of >=50% from baseline at Week 8, Week 16, Week 24 and Week 52 is presented.

F-calprotectin is an inflammatory marker for the gastrointestinal tract and considered as a measurement of neutrophil migration to the gastrointestinal tract. Percentage of participants with F-calprotectin reduction of >=75% compared to baseline at Week 8, Week 16, Week 24 and Week 52 is presented.

F-calprotectin is an inflammatory marker for the gastrointestinal tract and considered as a measurement of neutrophil migration to the gastrointestinal tract. Percentage of participants with F-calprotectin reduction of >=90% compared to baseline at Week 8, Week 16, Week 24 and Week 52 is presented.

F-calprotectin is an inflammatory marker for the gastrointestinal tract and considered as a measurement of neutrophil migration to the gastrointestinal tract. Percentage of participants reaching F-calprotectin below 250mg/kg at Week 8, Week 16, Week 24 and Week 52 in those participants who had F-calprotectin above 250 mg/kg at Baseline is presented.

F-calprotectin is an inflammatory marker for the gastrointestinal tract and considered as a measurement of neutrophil migration to the gastrointestinal tract. Higher values indicate more serious inflammation. Baseline was considered as date of initiation of tofacitinib.

Sustained remission in participants was defined as a full Mayo score of <=2 points, with no individual sub score exceeding 1 point with rectal bleeding sub-score of 0. Full Mayo score consisted of 4 sub scores: rectal bleeding, stool frequency, physician assessment of disease activity, and endoscopy findings, each ranged from 0 to 3 (0=normal, 1=mild, 2=moderate, 3=severe). These sub scores were summed up to give a total score range of 0 to 12, where higher scores indicated higher disease severity.

Sustained remission in participants was defined as a partial score of less than 2 points with rectal bleeding sub-score of 0. Partial Mayo score consisted of 3 sub scores: rectal bleeding, stool frequency, physician assessment of disease activity. Each sub score ranged from 0 to 3 (0=normal, 1=mild, 2=moderate, 3=severe). These sub scores were summed up to give a total score range of 0 to 9, where higher scores indicated higher disease severity.

Sustained remission in participants was defined as a full Mayo score of >=2 points, with no individual sub score exceeding 1 point with rectal bleeding sub-score of 0. Full Mayo score consisted of 4 sub scores: rectal bleeding, stool frequency, physician assessment of disease activity, and endoscopy findings, each sub score ranged from 0 to 3 (0=normal, 1=mild, 2=moderate, 3=severe). These sub scores were summed up to give a total score range of 0 to 12, where higher scores indicated higher disease severity.

Sustained remission in participants was defined as a partial score of less than 2 points with rectal bleeding sub-score of 0. Partial Mayo score consisted of 3 sub scores: rectal bleeding, stool frequency, physician assessment of disease activity. Each sub score ranged from 0 to 3 (0=normal, 1=mild, 2=moderate, 3=severe). These sub scores were summed up to give a total score range of 0 to 9, where higher scores indicated higher disease severity.

Clinical remission in participants was defined as a full Mayo score of <=2 points, with no individual sub score exceeding 1 point with rectal bleeding sub-score of 0. Full Mayo score consisted of 4 sub scores: rectal bleeding, stool frequency, physician assessment of disease activity, and endoscopy findings, each sub score ranged from 0 to 3 (0=normal, 1=mild, 2=moderate, 3=severe). These sub scores were summed up to give a total score range of 0 to 12, where higher scores indicated higher disease severity. Steroid-free clinical remission was defined as clinical remission in participants who were treated with corticosteroids at baseline and did not require any corticosteroid treatment during the period >=4 weeks prior to the visit.

Clinical remission in participants was defined as a partial score of less than 2 points with rectal bleeding sub-score of 0. Partial Mayo score consisted of 3 sub scores: rectal bleeding, stool frequency, physician assessment of disease activity. Each sub score ranged from 0 to 3 (0=normal, 1=mild, 2=moderate, 3=severe). These sub scores were summed up to give a total score range of 0 to 9, where higher scores indicated higher disease severity. Steroid-free clinical remission was defined as clinical remission in participants who were treated with corticosteroids at baseline and did not require any corticosteroid treatment during the period >=4 weeks prior to the visit.

Mayo score was an instrument designed to measure disease activity of UC. Full Mayo score consisted of 4 sub scores: rectal bleeding, stool frequency, physician assessment of disease activity, and endoscopy findings, each graded from 0 to 3 (0=normal, 1=mild, 2=moderate, 3=severe). These sub scores were summed up to give a total score range of 0 to 12, where higher scores indicated higher disease severity. Baseline was considered as date of initiation of tofacitinib.

Partial Mayo score consisted of 3 sub scores: rectal bleeding, stool frequency, physician assessment of disease activity. Each sub score ranged from 0 to 3 (0=normal, 1=mild, 2=moderate, 3=severe). These sub scores were summed up to give a total score range of 0 to 9, where higher scores indicated higher disease severity. Baseline was considered as date of initiation of tofacitinib.

Sustained endoscopic remission was defined as Mayo endoscopic sub score of 0. Mucosal healing = Mayo endoscopic sub score of 0 or 1. Endoscopic response= sub score reduction from baseline of >=1. The Mayo endoscopic sub score ranged from 0 to 3 (0=normal, 1=mild, 2=moderate, 3=severe). Higher sub scores indicated higher disease severity.

Physician assessed histological remission was defined as inactive disease or normal histology. Inactive disease was characterized by marked architectural abnormalities in the absence of active inflammation.

Histology assessment was categorized as, 1= inactive disease or normal histology and 2 = active disease. Inactive disease was characterized by marked architectural abnormalities in the absence of active inflammation. Active disease was characterized by absence of active inflammation. Baseline was considered as date of initiation of tofacitinib.

Sustained endoscopic remission was defined as Mayo endoscopic sub score of 0. Mucosal healing was defined by Mayo endoscopic sub score of 0 or 1. Endoscopic response was defined as sub score reduction from baseline of >=1. Full Mayo score consisted of 4 sub scores: rectal bleeding, stool frequency, physician assessment of disease activity, and endoscopy findings, each graded from 0 to 3 (0=normal, 1=mild, 2=moderate, 3=severe). These sub scores were summed up to give a total score range of 0 to 12, where higher scores indicated higher disease severity. Steroid-free clinical remission was defined as clinical remission in participants who were treated with corticosteroids at baseline and did not require any corticosteroid treatment during the period >=4 weeks prior to the visit.

Sustained endoscopic remission was defined as Mayo endoscopic sub score of 0. Mucosal healing was defined by Mayo endoscopic sub score of 0 or 1. Endoscopic response was defined as sub score reduction from baseline of >=1. Partial Mayo score consisted of 3 sub scores: rectal bleeding, stool frequency, physician assessment of disease activity. Each graded from 0 to 3 (0=normal, 1=mild, 2=moderate, 3=severe). These sub scores were summed up to give a total score range of 0 to 9, where higher scores indicated higher disease severity. Steroid-free clinical remission was defined as participants who were treated with corticosteroids at baseline and did not require any corticosteroid treatment during the period >=4 weeks prior to the visit.

Montreal classification was system used to classify UC based on the extent of inflammation. Three subgroups of UC were defined by extent of colonic involvement: E1= ulcerative proctitis: involvement limited to the rectum i.e, proximal extent of inflammation is distal to rectosigmoid junction, E2= left sided UC also known as distal colitis: involvement limited to portion of colorectum distal to the splenic flexure, E3= extensive UC (pancolitis): involvement extents proximal to splenic flexure. Clinical remission: full Mayo score of <=2 points, with no individual sub score exceeding 1 point with rectal bleeding sub-score of 0. Full Mayo score consisted of 4 sub scores: rectal bleeding, stool frequency, physician assessment of disease activity, & endoscopy findings, each sub score ranged from 0 to 3 (0=normal, 1=mild, 2=moderate, 3=severe). These sub scores were summed up to give total score range of 0 to 12. Higher scores indicated higher disease severity.

Montreal Classification was system used to classify UC based on the extent of inflammation. Three subgroups of UC were defined by extent of colonic involvement: E1= ulcerative proctitis: involvement limited to the rectum i.e, proximal extent of inflammation is distal to rectosigmoid junction, E2= left sided UC also known as distal colitis: involvement limited to portion of colorectum distal to the splenic flexure, E3= extensive UC (pancolitis): involvement extents proximal to splenic flexure. Clinical remission: partial score of less than 2 points with rectal bleeding sub-score of 0. Partial Mayo score consisted of 3 sub scores: rectal bleeding, stool frequency, physician assessment of disease activity. Each graded from 0 to 3 (0=normal, 1=mild, 2=moderate, 3=severe). These sub scores were summed up to give a total score range of 0 to 9, where higher scores indicated higher disease severity.

Montreal Classification was used to classify ulcerative colitis (UC) based on extent of inflammation. Three subgroups of UC were: E1= ulcerative proctitis: involvement limited to rectum i.e, proximal extent of inflammation is distal to rectosigmoid junction, E2= left sided, distal colitis: involvement limited to portion of colorectum distal to splenic flexure and E3= extensive UC (pancolitis): involvement extends proximal to the splenic flexure. Clinical response: full Mayo score decrease of >= 3 points & decrease of >=30% from baseline, with decrease of >=1 point on rectal bleeding sub score or an absolute rectal bleeding score of less than equal to (<=)1. Full Mayo score consisted of 4 sub scores: rectal bleeding, stool frequency, physician assessment of disease activity, and endoscopy findings, each graded from 0 to 3 (0=normal, 1=mild, 2=moderate, 3=severe). These sub scores were summed up to give a total score range of 0 to 12. Higher scores indicated higher disease severity.

Montreal Classification was used to classify ulcerative colitis (UC) based on extent of inflammation. Three subgroups of UC were: E1= ulcerative proctitis: involvement limited to rectum i.e, proximal extent of inflammation is distal to rectosigmoid junction, E2= left sided, distal colitis: involvement limited to portion of colorectum distal to splenic flexure and E3= extensive UC (pancolitis): involvement extends proximal to the splenic flexure. Clinical response: full Mayo score decrease of >=3 points and decrease of >=30% from baseline, with a decrease of >=1 point on rectal bleeding sub score or an absolute rectal bleeding score of less than equal to (<=)1. Partial Mayo score consisted of 3 sub scores: rectal bleeding, stool frequency, physician assessment of disease activity. Each graded from 0 to 3 (0=normal, 1=mild, 2=moderate, 3=severe). These sub scores were summed up to give a total score range of 0 to 9, where higher scores indicated higher disease severity.

Percentage of participants with corticosteroid tapering response was collected as Yes or No based on latest available data.

Corticosteroid tapering rate is reported in this outcome measure.

Stool frequency sub score ranged from 0 to 3, where, 0 = Normal, 1 = 1 to 2 stools per day more than normal, 2 = 3 to 4 stools per day more than normal, 3 = 5 or more stools per day than normal. Percentage of participants with improvement in stool frequency sub score of 1 or more points is presented.

Stool frequency sub score ranged from 0 to 3, where, 0 = Normal, 1 = 1 to 2 stools per day more than normal, 2 = 3 to 4 stools per day more than normal, 3 = 5 or more stools per day than normal.

Rectal bleeding sub scores ranged from 0 to 3, where, 0 = None, 1 = Visible blood with stool less than half the time, 2 = Visible blood with stool half of the time or more, 3 = Passing blood alone. Percentage of participants with improvement in rectal bleeding sub score of 1 or more points are presented.

Rectal bleeding sub scores ranged from 0 to 3, where, 0 = None, 1 = Visible blood with stool less than half the time, 2 = Visible blood with stool half of the time or more, 3 = Passing blood alone. Baseline was considered as initiation of tofacitinib.

Normal values for the parameters were as follows: P-CRP: below 4 milligrams per liter (mg/L), B-hb: men: 134 to 167 grams per liter (g/L), women: 117-155 g/L, B-leuk: 3.4 to 8.2*10^9 cells/L, B-Thromb: 150 to 360*10^9 cells/L, B-ly: 1.3 to3.6*10^9 cells/L, B-Neutr: 1.5 to6.7*10^9 cells/L, P-alb: 18 to 39 years: 36 to 48 g/L, 40 to 69 years: 36 to 45 g/L, 70 years and over: 34 to 45 g/L.

Baseline was considered as date of initiation of tofacitinib.

Baseline was considered as date of initiation of tofacitinib.

Baseline was considered as date of initiation of tofacitinib.

Percentage of participants with extended tofacitinib induction dose (additional 8 weeks with 10 mg) is presented in this outcome measure.

Percentage of participants with higher dose (10 mg) of tofacitinib (for all participants) is presented in this outcome measure.

Percentage of participants with higher (10 mg) dose of tofacitinib in participants who received treatment at different timepoints is presented in this outcome measure.

Time to survival without drug discontinuation, colectomy or UC-related hospitalization was calculated using time to event analysis.

Number of previous treatments received by participants is presented in this outcome measure.

Number of participants according to type of their previous treatment received is presented.

Clinical remission in participants was defined as a full Mayo score of <=2 points, with no individual sub score exceeding 1 point with rectal bleeding sub-score of 0. Full Mayo score consisted of 4 sub scores: rectal bleeding, stool frequency, physician assessment of disease activity, and endoscopy findings, each graded from 0 to 3 (0=normal, 1=mild, 2=moderate, 3=severe). These sub scores were summed up to give a total score range of 0 to 12, where higher scores indicated higher disease severity. Steroid-free clinical remission was defined as participants who were treated with corticosteroids at baseline and did not require any corticosteroid treatment during the period >=4 weeks prior to the visit.

Clinical remission in participants was defined as a partial Mayo score of less than 2 points with rectal bleeding sub-score of 0. Partial Mayo score consisted of 3 sub scores: rectal bleeding, stool frequency, physician assessment of disease activity. Each graded from 0 to 3 (0=normal, 1=mild, 2=moderate, 3=severe). These sub scores were summed up to give a total score range of 0 to 9, where higher scores indicated higher disease severity. Steroid-free clinical remission was defined for participants who were treated with corticosteroids at baseline and did not require any corticosteroid treatment during the period >=4 weeks prior to the visit.

F-calprotectin is an inflammatory marker for the gastrointestinal tract and considered as a measurement of neutrophil migration to the gastrointestinal tract. Percentage of Participants That had f-Calprotectin Above 250 mg/kg at Baseline is presented.

F-calprotectin is an inflammatory marker for the gastrointestinal tract and considered as a measurement of neutrophil migration to the gastrointestinal tract. Higher values indicate more serious inflammation. Baseline was considered as date of initiation of tofacitinib.

Clinical remission in participants was defined as a full Mayo score of <=2 points, with no individual sub score exceeding 1 point with rectal bleeding sub-score of 0. Full Mayo score consisted of 4 sub scores: rectal bleeding, stool frequency, physician assessment of disease activity, and endoscopy findings, each sub score ranged from 0 to 3 (0=normal, 1=mild, 2=moderate, 3=severe). These sub scores were summed up to give a total score range of 0 to 12, where higher scores indicated higher disease severity. Steroid-free clinical remission was defined as clinical remission in participants who were treated with corticosteroids at baseline and did not require any corticosteroid treatment during the period >=4 weeks prior to the visit.

Clinical remission in participants was defined as a partial score of less than 2 points with rectal bleeding sub-score of 0. Partial Mayo score consisted of 3 sub scores: rectal bleeding, stool frequency, physician assessment of disease activity. Each sub score ranged from 0 to 3 (0=normal, 1=mild, 2=moderate, 3=severe). These sub scores were summed up to give a total score range of 0 to 9, where higher scores indicated higher disease severity. Steroid-free clinical remission was defined as clinical remission in participants who were treated with corticosteroids at baseline and did not require any corticosteroid treatment during the period >=4 weeks prior to the visit.

Sustained endoscopic remission was defined as Mayo endoscopic sub score of 0. Mucosal healing was defined by Mayo endoscopic sub score of 0 or 1. Endoscopic response was defined as sub score reduction from baseline of >=1. Partial Mayo score consisted of 3 sub scores: rectal bleeding, stool frequency, physician assessment of disease activity. Each graded from 0 to 3 (0=normal, 1=mild, 2=moderate, 3=severe). These sub scores were summed up to give a total score range of 0 to 9, where higher scores indicated higher disease severity. Steroid-free clinical remission was defined as participants who were treated with corticosteroids at baseline and did not require any corticosteroid treatment during the period >=4 weeks prior to the visit.

Sustained endoscopic remission was defined as Mayo endoscopic sub score of 0. Mucosal healing was defined by Mayo endoscopic sub score of 0 or 1. Endoscopic response was defined as sub score reduction from baseline of >=1. Full Mayo score consisted of 4 sub scores: rectal bleeding, stool frequency, physician assessment of disease activity, and endoscopy findings, each graded from 0 to 3 (0=normal, 1=mild, 2=moderate, 3=severe). These sub scores were summed up to give a total score range of 0 to 12, where higher scores indicated higher disease severity. Steroid-free clinical remission was defined as clinical remission in participants who were treated with corticosteroids at baseline and did not require any corticosteroid treatment during the period >=4 weeks prior to the visit.

Absolute Values of Blood Hemoglobin and Plasma Albumin at Baseline are presented in this outcome measure.

Race and Ethnicity were not collected from any participant.

'Number Analyzed' signifies participants evaluable for specified rows.

'Number Analyzed' signifies participants evaluable for specified rows.

'Number Analyzed' signifies participants evaluable for specified rows.

'Number Analyzed' signifies participants evaluable for specified rows.

'Number Analyzed' signifies participants evaluable for specified rows.

'Number Analyzed' signifies participants evaluable for specified rows.

'Number Analyzed' signifies participants evaluable for specified rows.

Duration of ulcerative colitis was presented in this outcome measure. Index was considered as date of initiation of tofacitinib treatment for ulcerative colitis.

All eligible participants for whom data was collected and analyzed were included.

Montreal classification was used to classify UC based on extent of inflammation. Three subgroups of UC were: E1= ulcerative proctitis: involvement limited to rectum i.e, proximal extent of inflammation is distal to rectosigmoid junction, E2= left sided, distal colitis: involvement limited to portion of colorectum distal to splenic flexure and E3= extensive UC (pancolitis): involvement extends proximal to the splenic flexure. Index was considered as date of initiation of tofacitinib treatment for UC.

All eligible participants for whom data was collected and analyzed were included. Here, 'Number Analyzed' signifies participants evaluable at specified timepoints.

Mayo score was composed of four components: rectal bleeding, stool frequency, physician (doctors) assessment of disease activity, and endoscopy findings. Each sub score ranged from 0 to 3 (0=normal, 1=mild, 2=moderate, 3=severe). These sub scores were summed up to give a total score range of 0 to 12, where higher scores indicated higher disease severity. Index was considered as date of initiation of tofacitinib treatment for ulcerative colitis. Mayo scores and sub-scores have been collected by doctors independently as part of standard of care.

All eligible participants for whom data was collected and analyzed were included. "Overall Number of Participants Analyzed" signifies participants evaluable for this outcome measure.

Partial Mayo score consisted of 3 components: rectal bleeding, stool frequency, and physician (doctors) assessment of disease activity. Each sub score ranged from 0 to 3 (0=normal, 1=mild, 2=moderate, 3=severe). These sub scores were summed up to give a total score range of 0 to 9, where higher scores indicated higher disease severity. Index was considered as date of initiation of tofacitinib treatment for ulcerative colitis. Partial Mayo scores and sub-scores have been collected by doctors independently as part of standard of care.

All eligible participants for whom data was collected and analyzed were included. "Overall Number of Participants Analyzed" signifies participants evaluable for this outcome measure.

Endoscopic findings were graded from 0 to 3 where 0 = Normal or inactive disease (Normal vascular pattern with arborization of capillaries clearly defined, or with blurring or patchy loss of capillary margins), 1 = Mild disease (erythema, decreased vascular pattern, mild friability), 2 = Moderate disease (marked erythema, absent vascular pattern, friability, erosions), 3 = Severe disease (spontaneous bleeding, ulceration). Index was considered as date of initiation of tofacitinib treatment for ulcerative colitis.

All eligible participants for whom data was collected and analyzed were included. "Overall Number of Participants Analyzed" signifies participants evaluable for this outcome measure.

Endoscopic findings were graded from 0 to 3 where 0 = Normal or inactive disease, 1 = Mild disease (erythema, decreased vascular pattern, mild friability), 1 = Mild disease (erythema, decreased vascular pattern, mild friability), 3 = Severe disease (spontaneous bleeding, ulceration). Mayo score was composed of four components: rectal bleeding, stool frequency, physician assessment of disease activity and endoscopy findings. Each sub score ranged from 0 to 3 (0=normal, 1=mild, 2=moderate, 3=severe). These sub scores were summed up to give a total score range of 0 to 12, where higher scores indicated higher disease severity. Index was considered as date of initiation of tofacitinib treatment for ulcerative colitis.

All eligible participants for whom data was collected and analyzed were included. "Overall Number of Participants Analyzed" signifies participants evaluable for this outcome measure.

Percentage of participants who received tofacitinib is presented in this outcome measure.

All eligible participants for whom data was collected and analyzed were included. Here, 'Number Analyzed' signifies participants evaluable at specified timepoints.

Clinical remission in participants was defined as a full Mayo score of less than or equal to (<=) 2 points, with no individual sub score exceeding 1 point with rectal bleeding sub-score of 0. Full Mayo score consisted of 4 sub scores: rectal bleeding, stool frequency, physician assessment of disease activity, and endoscopy findings. Each subscore ranged from 0 to 3 (0=normal, 1=mild, 2=moderate, 3=severe). These sub scores were summed up to give a total score which ranged from 0 to 12, where higher scores indicated higher disease severity.

All eligible participants for whom data was collected and analyzed were included. 'Overall Number of Participants Analyzed' contributed data to table but may not have evaluable data for every row. Here, 'Number Analyzed' signifies participants evaluable at specified timepoints.

Clinical remission in participants was defined as a partial Mayo score of less than 2 points with rectal bleeding sub-score of 0. Partial Mayo score consisted of 3 sub scores: rectal bleeding, stool frequency, physician assessment of disease activity. Each sub score ranged from 0 to 3 (0=normal, 1=mild, 2=moderate, 3=severe). These sub scores were summed up to give a total score range of 0 to 9, where higher scores indicated higher disease severity.

All eligible participants for whom data was collected and analyzed were included. 'Overall Number of Participants Analyzed' contributed data to table but may not have evaluable data for every row. Here, 'Number Analyzed' signifies participants evaluable at specified timepoints.

Clinical response in participants was defined as a full Mayo score decrease of greater than or equal (>=) to 3 points and a decrease of >=30 percent (%) from baseline, with a decrease of >=1 point on the rectal bleeding sub score or an absolute rectal bleeding score of less than equal to (<=)1. Full Mayo score consisted of 4 sub scores: rectal bleeding, stool frequency, physician assessment of disease activity, and endoscopy findings. Each graded from 0 to 3 (0=normal, 1=mild, 2=moderate, 3=severe). These sub scores were summed up to give a total score range of 0 to 12, where higher scores indicated higher disease severity.

All eligible participants for whom data was collected and analyzed were included. 'Overall Number of Participants Analyzed' contributed data to table but may not have evaluable data for every row. Here, 'Number Analyzed' signifies participants evaluable at specified timepoints.

Clinical response in participants was defined as a partial Mayo score decrease of >=2 points and reduction of at least 25% in partial Mayo score from baseline with an accompanying decrease in rectal bleeding sub score of >=1 point or absolute rectal bleeding sub score of <=1. Partial Mayo score consisted of 3 sub scores: rectal bleeding, stool frequency, physician assessment of disease activity. Each graded from 0 to 3 (0=normal, 1=mild, 2=moderate, 3=severe). These sub scores were summed up to give a total score range of 0 to 9, where higher scores indicated higher disease severity.

All eligible participants for whom data was collected and analyzed were included. 'Overall Number of Participants Analyzed' contributed data to table but may not have evaluable data for every row. Here, 'Number Analyzed' signifies participants evaluable at specified timepoints.

Clinical remission in participants was defined as a full Mayo score of <=2 points, with no individual sub score exceeding 1 point with rectal bleeding sub-score of 0. Full Mayo score consisted of 4 sub scores: rectal bleeding, stool frequency, physician assessment of disease activity, and endoscopy findings, each graded from 0 to 3 (0=normal, 1=mild, 2=moderate, 3=severe). These sub scores were summed up to give a total score range of 0 to 12, where higher scores indicated higher disease severity.

All eligible participants for whom data was collected and analyzed were included. 'Overall Number of Participants Analyzed' contributed data to table but may not have evaluable data for every row. Here, 'Number Analyzed' signifies participants evaluable at specified timepoints.

Clinical remission in participants was defined as a partial Mayo score of less than 2 points with rectal bleeding sub-score of 0. Partial Mayo score consisted of 3 sub scores: rectal bleeding, stool frequency, physician assessment of disease activity. Each graded from 0 to 3 (0=normal, 1=mild, 2=moderate, 3=severe). These sub scores were summed up to give a total score range of 0 to 9, where higher scores indicated higher disease severity. Steroid-free clinical remission was defined for participants who were treated with corticosteroids at baseline and did not require any corticosteroid treatment during the period >=4 weeks prior to the visit.

All eligible participants for whom data was collected and analyzed were included. 'Overall Number of Participants Analyzed' contributed data to table but may not have evaluable data for every row. Here, 'Number Analyzed' signifies participants evaluable at specified timepoints.

Time to clinical response was analyzed using a competing risk time-to-event model, where clinical response and drug discontinuation were assessed. Clinical response in participants was defined as full Mayo score decrease of >=3 points & decrease of >=30% from baseline, with decrease of >=1 point on rectal bleeding sub score or absolute rectal bleeding score of <=1. Full Mayo score consisted of 4 sub scores: rectal bleeding, stool frequency, physician assessment of disease activity, & endoscopy findings. Each graded from 0 to 3 (0=normal, 1=mild, 2=moderate, 3=severe). Sub scores were summed up to give total score range: 0 to 12, Partial Mayo score consisted of 3 components without endoscopy findings. Each graded from 0 to 3, sub scores were summed up to give total score range: 0 to 9.Higher scores indicated higher disease severity.

All eligible participants for whom data was collected and analyzed were included. "Overall Number of Participants Analyzed" signifies participants evaluable for this outcome measure. Here, 'Number Analyzed' signifies maximum participants evaluable at specified timepoints.

F-calprotectin is an inflammatory marker for the gastrointestinal tract and considered as a measurement of neutrophil migration to the gastrointestinal tract. Percentage of participants with F-calprotectin reduction of >=50% from baseline at Week 8, Week 16, Week 24 and Week 52 is presented.

All eligible participants for whom data was collected and analyzed were included. 'Overall Number of Participants Analyzed' contributed data to table but may not have evaluable data for every row. Here, 'Number Analyzed' signifies participants evaluable at specified timepoints.

F-calprotectin is an inflammatory marker for the gastrointestinal tract and considered as a measurement of neutrophil migration to the gastrointestinal tract. Percentage of participants with F-calprotectin reduction of >=75% compared to baseline at Week 8, Week 16, Week 24 and Week 52 is presented.

All eligible participants for whom data was collected and analyzed were included. 'Overall Number of Participants Analyzed' contributed data to table but may not have evaluable data for every row. Here, 'Number Analyzed' signifies participants evaluable at specified timepoints.

F-calprotectin is an inflammatory marker for the gastrointestinal tract and considered as a measurement of neutrophil migration to the gastrointestinal tract. Percentage of participants with F-calprotectin reduction of >=90% compared to baseline at Week 8, Week 16, Week 24 and Week 52 is presented.

All eligible participants for whom data was collected and analyzed were included. 'Overall Number of Participants Analyzed' contributed data to table but may not have evaluable data for every row. Here, 'Number Analyzed' signifies participants evaluable at specified timepoints.

F-calprotectin is an inflammatory marker for the gastrointestinal tract and considered as a measurement of neutrophil migration to the gastrointestinal tract. Percentage of participants reaching F-calprotectin below 250mg/kg at Week 8, Week 16, Week 24 and Week 52 in those participants who had F-calprotectin above 250 mg/kg at Baseline is presented.

All eligible participants for whom data was collected and analyzed were included. Here, 'Number Analyzed' signifies participants evaluable at specified timepoints.

F-calprotectin is an inflammatory marker for the gastrointestinal tract and considered as a measurement of neutrophil migration to the gastrointestinal tract. Higher values indicate more serious inflammation. Baseline was considered as date of initiation of tofacitinib.

All eligible participants for whom data was collected and analyzed were included. Here, 'Number Analyzed' signifies participants evaluable at specified timepoints.

Sustained remission in participants was defined as a full Mayo score of <=2 points, with no individual sub score exceeding 1 point with rectal bleeding sub-score of 0. Full Mayo score consisted of 4 sub scores: rectal bleeding, stool frequency, physician assessment of disease activity, and endoscopy findings, each ranged from 0 to 3 (0=normal, 1=mild, 2=moderate, 3=severe). These sub scores were summed up to give a total score range of 0 to 12, where higher scores indicated higher disease severity.

All eligible participants for whom data was collected and analyzed were included. "Overall Number of Participants Analyzed" signifies participants evaluable for this outcome measure.

Sustained remission in participants was defined as a partial score of less than 2 points with rectal bleeding sub-score of 0. Partial Mayo score consisted of 3 sub scores: rectal bleeding, stool frequency, physician assessment of disease activity. Each sub score ranged from 0 to 3 (0=normal, 1=mild, 2=moderate, 3=severe). These sub scores were summed up to give a total score range of 0 to 9, where higher scores indicated higher disease severity.

All eligible participants for whom data was collected and analyzed were included. "Overall Number of Participants Analyzed" signifies participants evaluable for this outcome measure. Here, 'Number Analyzed' signifies participants evaluable at specified timepoints.

Sustained remission in participants was defined as a full Mayo score of >=2 points, with no individual sub score exceeding 1 point with rectal bleeding sub-score of 0. Full Mayo score consisted of 4 sub scores: rectal bleeding, stool frequency, physician assessment of disease activity, and endoscopy findings, each sub score ranged from 0 to 3 (0=normal, 1=mild, 2=moderate, 3=severe). These sub scores were summed up to give a total score range of 0 to 12, where higher scores indicated higher disease severity.

All eligible participants for whom data was collected and analyzed were included. Here, 'Number Analyzed' signifies participants evaluable at specified timepoints.

Sustained remission in participants was defined as a partial score of less than 2 points with rectal bleeding sub-score of 0. Partial Mayo score consisted of 3 sub scores: rectal bleeding, stool frequency, physician assessment of disease activity. Each sub score ranged from 0 to 3 (0=normal, 1=mild, 2=moderate, 3=severe). These sub scores were summed up to give a total score range of 0 to 9, where higher scores indicated higher disease severity.

All eligible participants for whom data was collected and analyzed were included. "Overall Number of Participants Analyzed" signifies participants evaluable for this outcome measure. Here, 'Number Analyzed' signifies participants evaluable at specified timepoints.

Clinical remission in participants was defined as a full Mayo score of <=2 points, with no individual sub score exceeding 1 point with rectal bleeding sub-score of 0. Full Mayo score consisted of 4 sub scores: rectal bleeding, stool frequency, physician assessment of disease activity, and endoscopy findings, each sub score ranged from 0 to 3 (0=normal, 1=mild, 2=moderate, 3=severe). These sub scores were summed up to give a total score range of 0 to 12, where higher scores indicated higher disease severity. Steroid-free clinical remission was defined as clinical remission in participants who were treated with corticosteroids at baseline and did not require any corticosteroid treatment during the period >=4 weeks prior to the visit.

All eligible participants for whom data was collected and analyzed were included. "Overall Number of Participants Analyzed" signifies participants evaluable for this outcome measure. Here, 'Number Analyzed' signifies participants evaluable at specified timepoints.

Clinical remission in participants was defined as a partial score of less than 2 points with rectal bleeding sub-score of 0. Partial Mayo score consisted of 3 sub scores: rectal bleeding, stool frequency, physician assessment of disease activity. Each sub score ranged from 0 to 3 (0=normal, 1=mild, 2=moderate, 3=severe). These sub scores were summed up to give a total score range of 0 to 9, where higher scores indicated higher disease severity. Steroid-free clinical remission was defined as clinical remission in participants who were treated with corticosteroids at baseline and did not require any corticosteroid treatment during the period >=4 weeks prior to the visit.

All eligible participants for whom data was collected and analyzed were included. "Overall Number of Participants Analyzed" signifies participants evaluable for this outcome measure. Here, 'Number Analyzed' signifies participants evaluable at specified timepoints.

Mayo score was an instrument designed to measure disease activity of UC. Full Mayo score consisted of 4 sub scores: rectal bleeding, stool frequency, physician assessment of disease activity, and endoscopy findings, each graded from 0 to 3 (0=normal, 1=mild, 2=moderate, 3=severe). These sub scores were summed up to give a total score range of 0 to 12, where higher scores indicated higher disease severity. Baseline was considered as date of initiation of tofacitinib.

All eligible participants for whom data was collected and analyzed were included. 'Overall Number of Participants Analyzed' contributed data to table but may not have evaluable data for every row. Here, 'Number Analyzed' signifies participants evaluable at specified timepoints.

Partial Mayo score consisted of 3 sub scores: rectal bleeding, stool frequency, physician assessment of disease activity. Each sub score ranged from 0 to 3 (0=normal, 1=mild, 2=moderate, 3=severe). These sub scores were summed up to give a total score range of 0 to 9, where higher scores indicated higher disease severity. Baseline was considered as date of initiation of tofacitinib.

All eligible participants for whom data was collected and analyzed were included. 'Overall Number of Participants Analyzed' contributed data to table but may not have evaluable data for every row. Here, 'Number Analyzed' signifies participants evaluable at specified timepoints.

Sustained endoscopic remission was defined as Mayo endoscopic sub score of 0. Mucosal healing = Mayo endoscopic sub score of 0 or 1. Endoscopic response= sub score reduction from baseline of >=1. The Mayo endoscopic sub score ranged from 0 to 3 (0=normal, 1=mild, 2=moderate, 3=severe). Higher sub scores indicated higher disease severity.

All eligible participants for whom data was collected and analyzed were included. "Overall Number of Participants Analyzed" signifies participants evaluable for this outcome measure. Here, 'Number Analyzed' signifies participants evaluable at specified timepoints.

Physician assessed histological remission was defined as inactive disease or normal histology. Inactive disease was characterized by marked architectural abnormalities in the absence of active inflammation.

All eligible participants for whom data was collected and analyzed were included. 'Overall Number of Participants Analyzed' contributed data to table but may not have evaluable data for every row. Here, 'Number Analyzed' signifies participants evaluable at specified timepoints.

Histology assessment was categorized as, 1= inactive disease or normal histology and 2 = active disease. Inactive disease was characterized by marked architectural abnormalities in the absence of active inflammation. Active disease was characterized by absence of active inflammation. Baseline was considered as date of initiation of tofacitinib.

All eligible participants for whom data was collected and analyzed were included. 'Overall Number of Participants Analyzed' contributed data to table but may not have evaluable data for every row. Here, 'Number Analyzed' signifies participants evaluable at specified timepoints.

Sustained endoscopic remission was defined as Mayo endoscopic sub score of 0. Mucosal healing was defined by Mayo endoscopic sub score of 0 or 1. Endoscopic response was defined as sub score reduction from baseline of >=1. Full Mayo score consisted of 4 sub scores: rectal bleeding, stool frequency, physician assessment of disease activity, and endoscopy findings, each graded from 0 to 3 (0=normal, 1=mild, 2=moderate, 3=severe). These sub scores were summed up to give a total score range of 0 to 12, where higher scores indicated higher disease severity. Steroid-free clinical remission was defined as clinical remission in participants who were treated with corticosteroids at baseline and did not require any corticosteroid treatment during the period >=4 weeks prior to the visit.

All eligible participants for whom data was collected and analyzed were included. "Overall Number of Participants Analyzed" signifies maximum number of participants evaluable for this outcome measure.

Sustained endoscopic remission was defined as Mayo endoscopic sub score of 0. Mucosal healing was defined by Mayo endoscopic sub score of 0 or 1. Endoscopic response was defined as sub score reduction from baseline of >=1. Partial Mayo score consisted of 3 sub scores: rectal bleeding, stool frequency, physician assessment of disease activity. Each graded from 0 to 3 (0=normal, 1=mild, 2=moderate, 3=severe). These sub scores were summed up to give a total score range of 0 to 9, where higher scores indicated higher disease severity. Steroid-free clinical remission was defined as participants who were treated with corticosteroids at baseline and did not require any corticosteroid treatment during the period >=4 weeks prior to the visit.

All eligible participants for whom data was collected and analyzed were included. "Overall Number of Participants Analyzed" signifies maximum number of participants evaluable for this outcome measure.

Montreal classification was system used to classify UC based on the extent of inflammation. Three subgroups of UC were defined by extent of colonic involvement: E1= ulcerative proctitis: involvement limited to the rectum i.e, proximal extent of inflammation is distal to rectosigmoid junction, E2= left sided UC also known as distal colitis: involvement limited to portion of colorectum distal to the splenic flexure, E3= extensive UC (pancolitis): involvement extents proximal to splenic flexure. Clinical remission: full Mayo score of <=2 points, with no individual sub score exceeding 1 point with rectal bleeding sub-score of 0. Full Mayo score consisted of 4 sub scores: rectal bleeding, stool frequency, physician assessment of disease activity, & endoscopy findings, each sub score ranged from 0 to 3 (0=normal, 1=mild, 2=moderate, 3=severe). These sub scores were summed up to give total score range of 0 to 12. Higher scores indicated higher disease severity.

All eligible participants for whom data was collected and analyzed were included. Here, 'Number Analyzed' signifies participants evaluable at specified timepoints.

Montreal Classification was system used to classify UC based on the extent of inflammation. Three subgroups of UC were defined by extent of colonic involvement: E1= ulcerative proctitis: involvement limited to the rectum i.e, proximal extent of inflammation is distal to rectosigmoid junction, E2= left sided UC also known as distal colitis: involvement limited to portion of colorectum distal to the splenic flexure, E3= extensive UC (pancolitis): involvement extents proximal to splenic flexure. Clinical remission: partial score of less than 2 points with rectal bleeding sub-score of 0. Partial Mayo score consisted of 3 sub scores: rectal bleeding, stool frequency, physician assessment of disease activity. Each graded from 0 to 3 (0=normal, 1=mild, 2=moderate, 3=severe). These sub scores were summed up to give a total score range of 0 to 9, where higher scores indicated higher disease severity.

All eligible participants for whom data was collected and analyzed were included. Here, 'Number Analyzed' signifies participants evaluable at specified timepoints.

Montreal Classification was used to classify ulcerative colitis (UC) based on extent of inflammation. Three subgroups of UC were: E1= ulcerative proctitis: involvement limited to rectum i.e, proximal extent of inflammation is distal to rectosigmoid junction, E2= left sided, distal colitis: involvement limited to portion of colorectum distal to splenic flexure and E3= extensive UC (pancolitis): involvement extends proximal to the splenic flexure. Clinical response: full Mayo score decrease of >= 3 points & decrease of >=30% from baseline, with decrease of >=1 point on rectal bleeding sub score or an absolute rectal bleeding score of less than equal to (<=)1. Full Mayo score consisted of 4 sub scores: rectal bleeding, stool frequency, physician assessment of disease activity, and endoscopy findings, each graded from 0 to 3 (0=normal, 1=mild, 2=moderate, 3=severe). These sub scores were summed up to give a total score range of 0 to 12. Higher scores indicated higher disease severity.

All eligible participants for whom data was collected and analyzed were included. Here, 'Number Analyzed' signifies participants evaluable at specified timepoints.

Montreal Classification was used to classify ulcerative colitis (UC) based on extent of inflammation. Three subgroups of UC were: E1= ulcerative proctitis: involvement limited to rectum i.e, proximal extent of inflammation is distal to rectosigmoid junction, E2= left sided, distal colitis: involvement limited to portion of colorectum distal to splenic flexure and E3= extensive UC (pancolitis): involvement extends proximal to the splenic flexure. Clinical response: full Mayo score decrease of >=3 points and decrease of >=30% from baseline, with a decrease of >=1 point on rectal bleeding sub score or an absolute rectal bleeding score of less than equal to (<=)1. Partial Mayo score consisted of 3 sub scores: rectal bleeding, stool frequency, physician assessment of disease activity. Each graded from 0 to 3 (0=normal, 1=mild, 2=moderate, 3=severe). These sub scores were summed up to give a total score range of 0 to 9, where higher scores indicated higher disease severity.

All eligible participants for whom data was collected and analyzed were included. Here, 'Number Analyzed' signifies participants evaluable at specified timepoints.

Percentage of participants with corticosteroid tapering response was collected as Yes or No based on latest available data.

All eligible participants for whom data was collected and analyzed were included.

Corticosteroid tapering rate is reported in this outcome measure.

All eligible participants for whom data was collected and analyzed were included.

All eligible participants for whom data was collected and analyzed were included.

Stool frequency sub score ranged from 0 to 3, where, 0 = Normal, 1 = 1 to 2 stools per day more than normal, 2 = 3 to 4 stools per day more than normal, 3 = 5 or more stools per day than normal. Percentage of participants with improvement in stool frequency sub score of 1 or more points is presented.

All eligible participants for whom data was collected and analyzed were included. 'Overall Number of Participants Analyzed' contributed data to table but may not have evaluable data for every row. Here, 'Number Analyzed' signifies participants evaluable at specified timepoints.

Stool frequency sub score ranged from 0 to 3, where, 0 = Normal, 1 = 1 to 2 stools per day more than normal, 2 = 3 to 4 stools per day more than normal, 3 = 5 or more stools per day than normal.

All eligible participants for whom data was collected and analyzed were included. Here, 'Number Analyzed' signifies participants evaluable at specified timepoints. 'Overall Number of Participants Analyzed' contributed data to table but may not have evaluable data for every row.

Rectal bleeding sub scores ranged from 0 to 3, where, 0 = None, 1 = Visible blood with stool less than half the time, 2 = Visible blood with stool half of the time or more, 3 = Passing blood alone. Percentage of participants with improvement in rectal bleeding sub score of 1 or more points are presented.

All eligible participants for whom data was collected and analyzed were included. 'Overall Number of Participants Analyzed' contributed data to table but may not have evaluable data for every row. Here, 'Number Analyzed' signifies participants evaluable at specified timepoints.

Rectal bleeding sub scores ranged from 0 to 3, where, 0 = None, 1 = Visible blood with stool less than half the time, 2 = Visible blood with stool half of the time or more, 3 = Passing blood alone. Baseline was considered as initiation of tofacitinib.

All eligible participants for whom data was collected and analyzed were included. 'Overall Number of Participants Analyzed' contributed data to table but may not have evaluable data for every row. Here, 'Number Analyzed' signifies participants evaluable at specified timepoints.

Normal values for the parameters were as follows: P-CRP: below 4 milligrams per liter (mg/L), B-hb: men: 134 to 167 grams per liter (g/L), women: 117-155 g/L, B-leuk: 3.4 to 8.2*10^9 cells/L, B-Thromb: 150 to 360*10^9 cells/L, B-ly: 1.3 to3.6*10^9 cells/L, B-Neutr: 1.5 to6.7*10^9 cells/L, P-alb: 18 to 39 years: 36 to 48 g/L, 40 to 69 years: 36 to 45 g/L, 70 years and over: 34 to 45 g/L.

All eligible participants for whom data was collected and analyzed were included. 'Overall Number of Participants Analyzed' contributed data to table but may not have evaluable data for every row. Here, 'Number Analyzed' signifies participants evaluable at specified timepoints.

Baseline was considered as date of initiation of tofacitinib.

All eligible participants for whom data was collected and analyzed were included. 'Overall Number of Participants Analyzed' contributed data to table but may not have evaluable data for every row. Here, 'Number Analyzed' signifies participants evaluable at specified timepoints.